SF2523

SF2523 is a novel, orally available small molecule that functions as a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and bromodomain-containing protein 4 (BRD4). It potently inhibits PI3K isoforms (notably PI3Kα and PI3Kγ), DNA-PK, BRD4, and mTOR. The drug was designed to simultaneously disrupt two key oncogenic pathways—PI3K/AKT/mTOR signaling and BRD4-mediated transcriptional regulation—resulting in maximal downregulation of MYC activity. This dual inhibition leads to anti-proliferative effects in cancer cells by blocking cell cycle progression, reducing tumor growth in vivo, suppressing immunosuppressive mechanisms within the tumor microenvironment, and promoting adaptive immune responses. Preclinical studies have demonstrated efficacy against renal cell carcinoma (RCC) and other solid tumors with minimal toxicity observed in animal models. SF2523 was initially developed by SignalRx Pharmaceuticals for oncology indications[1][2][6][7][8].